Market Overview:
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of CIDP, rising awareness about CIDP, and technological advancements in the treatment of CIDP. However, factors such as high cost of treatment and lack of awareness about CIDP in some regions are restraining the growth of the global chronic inflammatory demyelinating polyneuropathy (CIDP) market. Based on type, corticosteroid therapy is expected to account for the largest share of the global chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2018. This can be attributed to its high efficacy and relatively low cost as compared to other therapies available for treating CIPD. Based on application, hospital is expected to account for the largest share of the global chronic inflammatory demyelinating polyneuropathy (CIPD) market in 2018.
 Industry Outlook.svg)
Product Definition:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder that affects the peripheral nervous system. The peripheral nervous system includes all the nerves outside of the brain and spinal cord. CIDP causes damage to the myelin sheath, which is the protective covering around nerve fibers. This damage slows or interrupts communication between the brain and other parts of the body, leading to symptoms such as numbness, tingling, weakness, and pain.
Corticosteroid Therapy:
Corticosteroid therapy is used for the treatment of CIDP. It works by reducing the inflammation and pain caused by damaged nerves. Corticosteroids are also known to reduce the immune response which enables it to be used in patients who have undergone surgery (anaesthetized).
The use of corticosteroids has been approved in Europe.
IVIG Treatment:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a type of inflammatory autoimmune disorder affecting the peripheral nervous system. The cause of CIPD is still unknown and there has been no cure found so far. However, treatments such as immunosuppressants, IVIG treatments and monoclonal antibodies have shown promising results in clinical trials for treatment of this condition.
Application Insights:
On the basis of application, chronic inflammatory demyelinating polyneuropathy (CIDP) is segmented into hospital, specialty neurology clinic and research and academic laboratories. The hospital segment dominated the market in 2017 due to a large number of patients suffering from CIDP being admitted in hospitals across the globe. Moreover, an increase in healthcare expenditure along with rising prevalence of chronic diseases such as diabetes mellitus is anticipated to boost demand for new diagnostic tools and therapies which will further propel growth during the forecast period.
The specialty neurology clinics are expected to grow at a faster rate than research and academic laboratories over the forecast period owing to increasing incidence rates of CIPD coupled with high unmet needs for effective treatment options within clinical settings only.
Regional Analysis:
North America dominated the global chronic inflammatory demyelinating polyneuropathy market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate for new treatment methods are some of the factors responsible for its large share. In addition, increasing prevalence of CIDP is also expected to drive regional growth over the forecast period. For instance, according to data published by National Institute of Neurological Disorders & Strokes (NINDS), around 90 cases per million person per year were reported from U.S.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure and growing patient awareness levels regarding early diagnosis and treatment options for neuro-immune disorders coupled with supportive government initiatives pertaining towards quality care delivery system in emerging economies such as India & China & Singapore etc.
Growth Factors:
- Increasing incidence of CIDP due to growing awareness about the disease and its symptoms.
- Rising prevalence of autoimmune diseases that are associated with an increased risk of developing CIDP.
- Growing demand for better treatment options for CIDP patients, especially those with severe forms of the disease.
- increasing research funding for development of new and better therapies for CIDP patients 5 Increased focus on rare diseases such as CIDP by pharmaceutical companies, leading to more investment in R&D activities aimed at finding novel treatments for this condition
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report
By Type
Corticosteroid Therapy, IVIG Treatment, Plasma Exchange Therapy, Immunosuppressive Drug Therapy, Immunomodulator Therapy, Other, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
By Application
Hospital, Specialist Neurology Clinic, Research and Academic Laboratories
By Companies
Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, CSL Behring (CSL Limited), Bio Products Laboratory, Baxter, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report Segments:
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is segmented on the basis of:
Types
Corticosteroid Therapy, IVIG Treatment, Plasma Exchange Therapy, Immunosuppressive Drug Therapy, Immunomodulator Therapy, Other, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Specialist Neurology Clinic, Research and Academic Laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teijin Pharma
- Shire
- Pfizer
- Octapharma
- Momenta Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
- Kedrion
- Grifols
- CSL Behring (CSL Limited)
- Bio Products Laboratory
- Baxter
- MedDay Pharmaceuticals
- GeNeuro Pharmaceuticals
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
 Market Overview.svg)
Highlights of The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroid Therapy
- IVIG Treatment
- Plasma Exchange Therapy
- Immunosuppressive Drug Therapy
- Immunomodulator Therapy
- Other
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
- By Application:
- Hospital
- Specialist Neurology Clinic
- Research and Academic Laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare, chronic condition that affects the nervous system. The nerves become inflamed and damaged over time, leading to problems with movement and sensation. CIDP can be very disabling and often requires long-term treatment.
Some of the major companies in the chronic inflammatory demyelinating polyneuropathy (cidp) market are Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols, CSL Behring (CSL Limited), Bio Products Laboratory, Baxter, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP.
The chronic inflammatory demyelinating polyneuropathy (cidp) market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Supply Chain
4.5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Forecast
4.5.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Absolute $ Opportunity
5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Type
5.3.1. Corticosteroid Therapy
5.3.2. IVIG Treatment
5.3.3. Plasma Exchange Therapy
5.3.4. Immunosuppressive Drug Therapy
5.3.5. Immunomodulator Therapy
5.3.6. Other
5.3.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Specialist Neurology Clinic
6.3.3. Research and Academic Laboratories
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Demand Share Forecast, 2019-2026
9. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Specialist Neurology Clinic
9.4.3. Research and Academic Laboratories
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Type
9.7.1. Corticosteroid Therapy
9.7.2. IVIG Treatment
9.7.3. Plasma Exchange Therapy
9.7.4. Immunosuppressive Drug Therapy
9.7.5. Immunomodulator Therapy
9.7.6. Other
9.7.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Demand Share Forecast, 2019-2026
10. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Specialist Neurology Clinic
10.4.3. Research and Academic Laboratories
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Type
10.7.1. Corticosteroid Therapy
10.7.2. IVIG Treatment
10.7.3. Plasma Exchange Therapy
10.7.4. Immunosuppressive Drug Therapy
10.7.5. Immunomodulator Therapy
10.7.6. Other
10.7.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Demand Share Forecast, 2019-2026
11. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Specialist Neurology Clinic
11.4.3. Research and Academic Laboratories
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Type
11.7.1. Corticosteroid Therapy
11.7.2. IVIG Treatment
11.7.3. Plasma Exchange Therapy
11.7.4. Immunosuppressive Drug Therapy
11.7.5. Immunomodulator Therapy
11.7.6. Other
11.7.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Demand Share, 2019-2026
12. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Specialist Neurology Clinic
12.4.3. Research and Academic Laboratories
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Type
12.7.1. Corticosteroid Therapy
12.7.2. IVIG Treatment
12.7.3. Plasma Exchange Therapy
12.7.4. Immunosuppressive Drug Therapy
12.7.5. Immunomodulator Therapy
12.7.6. Other
12.7.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Demand Share, 2019-2026
13. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Specialist Neurology Clinic
13.4.3. Research and Academic Laboratories
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Volume Forecast by Type
13.7.1. Corticosteroid Therapy
13.7.2. IVIG Treatment
13.7.3. Plasma Exchange Therapy
13.7.4. Immunosuppressive Drug Therapy
13.7.5. Immunomodulator Therapy
13.7.6. Other
13.7.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Market Share Analysis
14.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Distributors and Customers
14.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teijin Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Shire
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Octapharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Momenta Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Mitsubishi Tanabe Pharma Corporation
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Kedrion
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Grifols
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. CSL Behring (CSL Limited)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bio Products Laboratory
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Baxter
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. MedDay Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. GeNeuro Pharmaceuticals
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17.
